Biography
Souleymane M. Bassirou, born in Niamey (Niger) in 1982, has more than 8 years of experience in Public Health, working in low-income countries in Africa. He is a clinician with expertise in tuberculosis care, including MDR/RR-TB (7 years). He is the PI of trials evaluating treatment regimens for rifampicin-susceptible and rifampicin-resistant TB. He works with Damien Foundation as country representative, medical advisor of the country NTP, and PhD student affiliated with the Institute of Tropical Medicine Antwerp. He provides technical assistance to NTPs and teaches at National and International TB, MDR-TB and active drug safety monitoring (aDSM) courses.
Key Impacts
Safety and efficacy of an adaptive injectable-containing regimen for rifampicin-resistant-TB: Results from the SHOORT trial in Niger
Short-term use of SLID with audiometric monitoring and selective LZD substitution is safer than long-term LZD exposure, without compromising efficacy.Table 1: Safety and efficacy results of an all-oral versus an adaptive short treatment regimenSafety population§oSTRN = 161aSTRN = 135p-valueSevere grade 3-4 AE45 (28.0%)18 (13.3%)0.002Efficacy populationoSTRN = 148aSTRN = 124p-valueFavorable outcomes45 (79.05%)103 (83.06%)0.7Unfavorable outcomesOf which31 (20.9%)21 (16.9%) Died27 (18.2%)19 (15.3%) Failure3 (2.0%)0 (0.0%) Relapse1 (0.6%)2 (1.6%)§22 excluded: 21 losses to follow-up (10 oSTR, 11 aSTR) and 1 fluoroquinolone resistance detected a posteriori (oSTR)Abbreviations: oSTR: all-oral bedaquiline linezolid containing short treatment regiment, aSTR: adaptive short treatment regimen, AE: adverse event.
Source: Conference 2024
TRIDORE: Intensive-phase-throughout regimen is safer and more efficacious than triple-dose regimen for retreatment of rifampicin-susceptible TB
In patients in need of retreatment for rifampicin-susceptible TB, the TRIDORE trial showed that a triple-dose regimen was not non-inferior compared to an intensive-phase-throughout regimen in terms of safety. The triple-dose regimen was associated with both the occurrence of unfavorable safety and treatment outcomes. We propose the intensive-phase-throughout regimen for the retreatment of rifampicin-susceptible TB.
Source: Conference 2024
Against all odds: Reduction of drug-resistant TB incidence in Niger, a public health success story
Impact details available upon request.
Source: Conference 2024